Katina Dorton is a corporate director and former public company CFO with deep Wall Street and capital markets experience. She serves on the Board of Directors of Keenova Therapeutics, T Scan Therapeutics, Fulcrum Therapeutics and Prelude Therapeutics, and has held numerous board leadership roles, including lead independent director and chair of audit, compensation, and governance committees.

Dorton has held CFO positions at both public and private biotechnology companies, including Nodthera, Inc., Repare Therapeutics, AVROBIO, and Immatics GmbH. Previously, she spent more than 15 years as a managing director in at Morgan Stanley, leading global businesses, and practiced M&A and securities law at Sullivan & Cromwell.

An NACD Certified Director and Corporate Governance Fellow, Dorton served on the Board of the NACD Research Triangle Chapter for 10 years.

She holds a JD from the University of Virginia School of Law, an MBA. from George Washington University, and a BA from Duke University.